Biolog PRESS RELEASES - Biolog Inc.

微生物学与细胞生物学的
创新技术产品

 
 
 

Press Releases

For Immediate Release
Thursday, October 21, 2004
 
Contact: Tim Mullane
  Biolog, Inc.
  (510) 785-2564 ext. 319
 
BIOLOG AWARDED NIH STTR GRANT WITH WASHINGTON UNIVERSITY TO DEVELOP PHENOTYPE MICROARRAY™ TECHNOLOGY FOR FASTIDIOUS PATHOGENS
 

Hayward, CA- October 21, 2004 - Biolog, Inc. announced today that it has been awarded a STTR grant from the National Institutes of Health to collaborate with Washington University , St. Louis , Missouri . This grant will be to develop Biolog’s innovative Phenotype MicroArray™ (PM) technology for use with fastidious pathogens. Specifically the technology will be applied to the organisms Helicobacter pylori and Campylobacter jejuni. These organisms will be added to the expanding capability of the PM technology for testing microbial cells, specifically bacteria, yeast, and filamentous fungi.

Phenotype MicroArrays represent a fundamental technology platform, which allows scientists to easily and efficiently test hundreds to thousands of cellular traits simultaneously. The technology has the promise of determining cellular phenotypic expression in many areas of research. The two most important near term applications are using PMs to determine the effect of genetic changes on cells and to determine the effect of drugs on cells. The Centers for Disease Control estimate that Helicobacter pylori, the cause of peptic ulcers, will affect over 25 million Americans in their lifetime, while Campylobacter jejuni, one of the etiological agents associated with food poisoning, affects over 1 million Americans annually. This collaborative work is specifically intended to further the understanding of these serious pathogens and provide new insight into how to combat infections from these bacteria. Biolog, Inc. enables a systematic approach to cellular studies by providing assays, fully automated instrumentation, and software to generate kinetic response curves from the cell lines being analyzed.

Biolog, a privately held company based in Hayward , CA , is a pioneer in the development of powerful new cell analysis tools for solving critical problems in clinical, pharmaceutical, and biotechnology research and development. The company’s Phenotype MicroArray technology and OmniLog® PM System can be used in the discovery and development of new drugs as well as bioactive agents for animal and plant applications. Further information can be obtained at the company’s website, www.biolog.com.